麦德佩斯临床研究
MEDP
618.47
-10.13
-1.61%
麦德佩斯临床研究
US · MEDP
#1015 按市值排名
上市于 2016
618.47
-10.13
-1.61%
实时 - 追踪5344个代码 - 心跳于166秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了4家。
- 机构持股总比例下降了0.2个百分点。
机构持股
- 机构持股比例
- 89.65% -0.24pp
- 机构数量
- 830 -4
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund72.40%
Individual/Insider18.75%
Hedge Fund7.86%
Public Company4.88%
Government Pension Fund2.18%
Private Company0.82%
Sovereign Wealth Fund0.82%
Family Office/Trust0.35%
Insurance Company0.25%
主要股东 截至 2026-09-30
August Troendle
18.17% · 5.07M 股
BlackRock
8.95% · 2.50M 股
T. Rowe Price Group, Inc.
7.42% · 2.07M 股
AQR Capital Management
4.55% · 1.27M 股
Vanguard Capital Management, LLC
4.20% · 1.17M 股
Vanguard Portfolio Management, LLC
4.06% · 1.13M 股
State Street Global Advisors
2.55% · 710.90K 股
Geode Capital Management, LLC
2.55% · 710.47K 股
Wasatch Advisors LP
2.28% · 636.60K 股
Invesco Capital Management LLC
1.82% · 508.78K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 23次买入 · 24次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| August Troendle | Chairperson & CEO | 18.17% |
| Susan Burwig | Officer | 0.24% |
| Brian Carley | Independent Director | 0.10% |
| Stephen Ewald | Chief Compliance Officer, General Counsel & Corporate Secretary | 0.07% |
| Jesse Geiger | President | 0.05% |
| Kevin Brady | Chief Financial Officer | 0.05% |
| Cornelius McCarthy | Independent Director | 0.04% |
| Fred Davenport | Lead Independent Director | 0.02% |
| Robert Kraft | Independent Director | 0.00% |
| Brad Hansman | Officer | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-29 | Cornelius McCarthy | Independent Director | Derivative Exercise and Retained | +28 | -- |
| 2026-09-29 | August Troendle | Chairperson & CEO | Open Market Disposition | -48,667 | $621.02–625.47 |
| 2026-09-29 | Robert Kraft | Independent Director | Derivative Exercise and Retained | +32 | -- |
| 2026-09-29 | Brian Carley | Independent Director | Derivative Exercise and Retained | +36 | -- |
| 2026-09-27 | August Troendle | Chairperson & CEO | Open Market Disposition | -2,564 | $620.07–620.60 |
| 2026-09-23 | August Troendle | Chairperson & CEO | Open Market Disposition | -43,916 | $621.33–628.64 |
| 2026-09-21 | August Troendle | Chairperson & CEO | Open Market Disposition | -70,901 | $623.29–628.11 |
| 2026-09-16 | August Troendle | Chairperson & CEO | Open Market Disposition | -10,880 | $620.40 |
| 2026-09-15 | August Troendle | Chairperson & CEO | Open Market Disposition | -24,741 | $620.84–621.29 |
| 2026-09-14 | Susan Burwig | Officer | Derivative Exercise and Retained | +3,000 | $166.73 |
| 2026-08-26 | August Troendle | Chairperson & CEO | Open Market Disposition | -650 | $620.27 |
| 2026-08-25 | August Troendle | Chairperson & CEO | Open Market Disposition | -4,673 | $620.03–620.38 |
| 2026-08-25 | Robert Kraft | Independent Director | Derivative Exercise and Sale | -3,858 | $84.36–617.81 |
| 2026-08-23 | August Troendle | Chairperson & CEO | Open Market Disposition | -15,978 | $620.23–624.45 |
| 2026-08-19 | August Troendle | Chairperson & CEO | Open Market Disposition | -42,783 | $606.47–618.79 |
| 2026-08-19 | Kevin Brady | Chief Financial Officer | Derivative Exercise and Sale | -3,400 | $138.87–625.24 |
| 2026-08-18 | Fred Davenport | Lead Independent Director | Derivative Exercise and Sale | -7,283 | $84.36–606.15 |
| 2026-08-18 | Fred Davenport | Lead Independent Director | Derivative Exercise and Retained | +300 | $133.87 |
| 2026-08-18 | Brian Carley | Independent Director | Open Market Disposition | -5,000 | $608.63 |
| 2026-08-12 | August Troendle | Chairperson & CEO | Open Market Disposition | -11,824 | $600.39–601.53 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
麦德佩斯临床研究 讨论区 0 条评论